Buscar
Mostrando ítems 1-2 de 2
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials
(Willey Online Library, 2020-09-20)
[Abstract]
Aims
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
(Massachusetts Medical Society, 2020-11-13)
[Abstract]
BACKGROUND.
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction.
Its effect on cardiovascular ...